Sofinnova Investments, Inc.
CIK: 0001631134Latest portfolio: $2.3B · Q4 2025
Holdings
60
Total Value
$2.3B
New Positions
11
Closed Positions
10
Top Holdings
View All 60 Holdings →| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | NTRANATERA INC | 1,550,280 | $355.2M | 15.31% | — | |
| 2 | JAZZJAZZ PHARMACEUTICALS PLC | 959,860 | $163.2M | 7.04% | +371K | |
| 3 | AZNASTRAZENECA PLC | 1,632,334 | $150.1M | 6.47% | +808K | |
| 4 | VERAVERA THERAPEUTICS INC | 2,793,987 | $141.5M | 6.10% | — | |
| 5 | BMYBRISTOL-MYERS SQUIBB CO | 1,512,994 | $81.6M | 3.52% | NEW | |
| 6 | UTHUNITED THERAPEUTICS CORP | 157,641 | $76.8M | 3.31% | NEW | |
| 7 | VRTXVERTEX PHARMACEUTICALS INC | 164,594 | $74.6M | 3.22% | +47K | |
| 8 | ABBVABBVIE INC | 317,783 | $72.6M | 3.13% | +167K | |
| 9 | ISRGINTUITIVE SURGICAL INC | 126,968 | $71.9M | 3.10% | +16K | |
| 10 | COGTCOGENT BIOSCIENCES INC | 1,973,625 | $70.1M | 3.02% | -154,316 | |
| 11 | LLYELI LILLY & CO | 61,652 | $66.3M | 2.86% | NEW | |
| 12 | RAPPRAPPORT THERAPEUTICS INC | 1,904,408 | $57.8M | 2.49% | -43,171 | |
| 13 | BBIOBRIDGEBIO PHARMA INC | 720,448 | $55.1M | 2.38% | -111,399 | |
| 14 | RNAAVIDITY BIOSCIENCES INC | 745,116 | $53.7M | 2.32% | -130,809 | |
| 15 | DYNDYNE THERAPEUTICS INC | 2,254,161 | $44.1M | 1.90% | +1.3M | |
| 16 | BMRNBIOMARIN PHARMACEUTICAL INC | 697,133 | $41.4M | 1.79% | NEW | |
| 17 | APGEAPOGEE THERAPEUTICS INC | 534,845 | $40.4M | 1.74% | -30,572 | |
| 18 | CDTXCIDARA THERAPEUTICS INC | 180,265 | $39.8M | 1.72% | +126K | |
| 19 | PRAXPRAXIS PRECISION MEDICINES INC | 125,722 | $37.1M | 1.60% | -47,111 | |
| 20 | IMTXIMMATICS N.V | 3,435,542 | $36.1M | 1.56% | +1.2M | |
| 21 | INBXINHIBRX BIOSCIENCES INC | 454,657 | $35.9M | 1.55% | +15K | |
| 22 | IMNMIMMUNOME INC | 1,618,477 | $34.8M | 1.50% | +1.2M | |
| 23 | AVBPARRIVENT BIOPHARMA INC | 1,696,752 | $34.1M | 1.47% | — | |
| 24 | GKOSGLAUKOS CORP | 288,128 | $32.5M | 1.40% | -24,866 | |
| 25 | IDYAIDEAYA BIOSCIENCES INC | 885,121 | $30.6M | 1.32% | -37,574 |
Quarterly Changes
New Positions
Increased Positions
Sector Breakdown
Healthcare0.0% ($3.5515316317615004e+245T)
Unknown0.0% ($7681039818272891904.0T)
Filing History
| Quarter | Filing Date | Portfolio Value | Holdings |
|---|---|---|---|
| Q4 2025 | Feb 13, 2026 | $2.3B | 60 |
| Q3 2025 | Nov 14, 2025 | $1.8T | 62 |
| Q2 2025 | Aug 14, 2025 | $1.6T | 63 |
| Q1 2025 | May 15, 2025 | $1.5T | 65 |
| Q4 2024 | Feb 14, 2025 | $1.4T | 61 |
| Q3 2024 | Nov 13, 2024 | $1260.0T | 62 |
| Q2 2024 | Aug 9, 2024 | $1924.2T | 82 |
| Q1 2024 | May 15, 2024 | $1795.1T | 74 |
| Q4 2023 | Feb 13, 2024 | $1787.1T | 64 |
| Q3 2023 | Nov 14, 2023 | $1585.2T | 69 |
| Q2 2023 | Aug 14, 2023 | $1526.8T | 55 |
| Q1 2023 | May 11, 2023 | $1563.6T | 53 |
| Q4 2022 | Feb 14, 2023 | $1685.2T | 53 |
| Q3 2022 | Nov 8, 2022 | $1.7T | 61 |
| Q2 2022 | Aug 15, 2022 | $1.2T | 61 |
| Q1 2022 | May 16, 2022 | $1.3T | 64 |
| Q4 2021 | Feb 14, 2022 | $1.7T | 72 |
| Q3 2021 | Nov 15, 2021 | $1.7T | 70 |
| Q2 2021 | Aug 16, 2021 | $1.7T | 67 |
| Q1 2021 | May 14, 2021 | $1.7T | 64 |
| Q4 2020 | Feb 16, 2021 | $1.7T | 69 |
| Q3 2020 | Nov 13, 2020 | $1.3T | 157 |
| Q2 2020 | Aug 13, 2020 | $1.6T | 186 |
| Q1 2020 | May 13, 2020 | $1.1T | 150 |
| Q4 2019 | Feb 14, 2020 | $1.4T | 135 |
| Q3 2019 | Nov 14, 2019 | $1.1T | 167 |
| Q2 2019 | Aug 13, 2019 | $1.1T | 163 |
| Q1 2019 | May 15, 2019 | $1.0T | 164 |
| Q4 2018 | Feb 14, 2019 | $767.9B | 136 |
| Q3 2018 | Nov 15, 2018 | $1.1T | 144 |
| Q2 2018 | Aug 14, 2018 | $685.3B | 59 |
| Q1 2018 | May 15, 2018 | $581.8B | 55 |
Fund Information
Sofinnova Investments, Inc. is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $2.3B across 60 holdings. The largest position is NATERA INC (NTRA), representing 15.3% of the portfolio. Compared to the previous quarter, the fund opened 13 new positions and closed 12 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.